听力与言语-语言病理学

行为科学

医学伦理学

你正在浏览Cancer Immunology Research期刊下所有文献
  • Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice.

    abstract::The prognosis is very dismal for patients with relapsed CD20(+) B-cell non-Hodgkin lymphoma (B-NHL). Facilitating the development of alternative novel therapeutic strategies is required to improve outcomes in patients with recurrent/refractory CD20(+) B-NHL. In this study, we investigated functional activities of anti...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-14-0114

    authors: Chu Y,Hochberg J,Yahr A,Ayello J,van de Ven C,Barth M,Czuczman M,Cairo MS

    更新日期:2015-04-01 00:00:00

  • c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity.

    abstract::Monoclonal antibodies (mAb) can modulate cancer cell signal transduction and recruit antitumor immune effector mechanisms-including antibody-dependent cellular cytotoxicity (ADCC). Although several clinically effective antibodies can promote ADCC, therapeutic resistance is common. We hypothesized that oncogenic signal...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-14-0083

    authors: Murray JC,Aldeghaither D,Wang S,Nasto RE,Jablonski SA,Tang Y,Weiner LM

    更新日期:2014-12-01 00:00:00

  • Murine splenic CD4⁺ T cells, induced by innate immune cell interactions and secreted factors, develop antileukemia cytotoxicity.

    abstract::Inciting the cellular arm of adaptive immunity has been the fundamental goal of cancer immunotherapy strategies, specifically focusing on inducing tumor antigen-specific responses by CD8(+) cytotoxic T lymphocytes (CTL). However, there is an emerging appreciation that the cytotoxic function of CD4(+) T cells can be ef...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-13-0208

    authors: Nelles ME,Moreau JM,Furlonger CL,Berger A,Medin JA,Paige CJ

    更新日期:2014-11-01 00:00:00

  • The path to reactivation of antitumor immunity and checkpoint immunotherapy.

    abstract::Cancer immunology has recently made major therapeutic inroads that represent clinical application of basic insights into mechanisms that govern immunity against tumors. Research into fundamental elements of T-cell and natural killer-cell biology, including the basis of antigen recognition, activation, proliferation, a...

    journal_title:Cancer immunology research

    pub_type: 杂志文章,评审

    doi:10.1158/2326-6066.CIR-14-0153

    authors: Kim HJ,Cantor H

    更新日期:2014-10-01 00:00:00

  • CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.

    abstract::Natural killer (NK) cells contribute to clinical responses in patients treated with rituximab, but the rules determining NK-cell responsiveness to mAb therapies are poorly defined. A deeper understanding of the mechanisms responsible for antibody-dependent cellular cytotoxicity (ADCC) could yield useful biomarkers for...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-13-0158

    authors: Du J,Lopez-Verges S,Pitcher BN,Johnson J,Jung SH,Zhou L,Hsu K,Czuczman MS,Cheson B,Kaplan L,Lanier LL,Venstrom JM

    更新日期:2014-09-01 00:00:00

  • Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells.

    abstract::Antibody-drug conjugates (ADC) are emerging as powerful treatment strategies with outstanding target-specificity and high therapeutic activity in patients with cancer. Brentuximab vedotin represents a first-in-class ADC directed against CD30(+) malignancies. We hypothesized that its sustained clinical responses could ...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-13-0198

    authors: Müller P,Martin K,Theurich S,Schreiner J,Savic S,Terszowski G,Lardinois D,Heinzelmann-Schwarz VA,Schlaak M,Kvasnicka HM,Spagnoli G,Dirnhofer S,Speiser DE,von Bergwelt-Baildon M,Zippelius A

    更新日期:2014-08-01 00:00:00

  • Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists.

    abstract::Hypoxia-driven, A2A adenosine receptor (A2AR)-mediated (hypoxia-A2-adenosinergic), T-cell-autonomous immunosuppression was first recognized as critical and nonredundant in protecting normal tissues from inflammatory damage and autoimmunity. However, this immunosuppressive mechanism can be highjacked by bacteria and tu...

    journal_title:Cancer immunology research

    pub_type: 杂志文章,评审

    doi:10.1158/2326-6066.CIR-14-0075

    authors: Sitkovsky MV,Hatfield S,Abbott R,Belikoff B,Lukashev D,Ohta A

    更新日期:2014-07-01 00:00:00

  • Tumor MHC class I expression improves the prognostic value of T-cell density in resected colorectal liver metastases.

    abstract::Tumor-infiltrating lymphocytes (TIL) in colorectal cancer liver metastases (CLM) have been associated with more favorable patient outcomes, but whether MHC class I (MHC-I) expression on cancer cells affects prognosis is uncertain. Immunohistochemistry was performed on a tissue microarray of 158 patients with CLM, who ...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-13-0180

    authors: Turcotte S,Katz SC,Shia J,Jarnagin WR,Kingham TP,Allen PJ,Fong Y,D'Angelica MI,DeMatteo RP

    更新日期:2014-06-01 00:00:00

  • Cancer-testis antigen expression in digestive tract carcinomas: frequent expression in esophageal squamous cell carcinoma and its precursor lesions.

    abstract::Cancer-testis (CT) antigens are attractive tumor antigens for cancer immunotherapy. They comprise a group of proteins normally expressed in germ cells and aberrantly activated in a variety of human cancers. The protein expression of eight cancer-testis antigens [MAGEA, NY-ESO-1, GAGE, MAGEC1 (CT7), MAGEC2 (CT10), CT45...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-13-0124

    authors: Chen YT,Panarelli NC,Piotti KC,Yantiss RK

    更新日期:2014-05-01 00:00:00

  • Affinity enhancement of antibodies: how low-affinity antibodies produced early in immune responses are followed by high-affinity antibodies later and in memory B-cell responses.

    abstract::The antibodies produced initially in response to most antigens are high molecular weight (MW) immunoglobulins (IgM) with low affinity for the antigen, while the antibodies produced later are lower MW classes (e.g., IgG and IgA) with, on average, orders of magnitude higher affinity for that antigen. These changes, ofte...

    journal_title:Cancer immunology research

    pub_type: 杂志文章,评审

    doi:10.1158/2326-6066.CIR-14-0029

    authors: Eisen HN

    更新日期:2014-05-01 00:00:00

  • Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome.

    abstract::The presence of regulatory T cells (Treg) in solid tumors is known to play a role in patient survival in ovarian cancer and other malignancies. We assessed inherited genetic variations via 749 tag single-nucleotide polymorphisms (SNP) in 25 Treg-associated genes (CD28, CTLA4, FOXP3, IDO1, IL10, IL10RA, IL15, 1L17RA, I...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-13-0136

    authors: Charbonneau B,Moysich KB,Kalli KR,Oberg AL,Vierkant RA,Fogarty ZC,Block MS,Maurer MJ,Goergen KM,Fridley BL,Cunningham JM,Rider DN,Preston C,Hartmann LC,Lawrenson K,Wang C,Tyrer J,Song H,deFazio A,Johnatty SE,Doher

    更新日期:2014-04-01 00:00:00

  • Untreated stage IV melanoma patients exhibit abnormal monocyte phenotypes and decreased functional capacity.

    abstract::Monocytes may contribute to tumor progression in part by mediating tumor-induced immunosuppression. Alterations to the monocyte populations and functions in untreated patients with late-stage melanoma are not fully understood. To characterize these alterations, we compared the frequency, phenotype, and functional capa...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-13-0094

    authors: Chavan R,Salvador D,Gustafson MP,Dietz AB,Nevala W,Markovic SN

    更新日期:2014-03-01 00:00:00

  • CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy.

    abstract::The transcription factor T-bet controls the Th1 genetic program in T cells for effective antitumor responses. Anti-CTLA-4 immunotherapy elicits dramatic antitumor responses in mice and in human patients; however, factors that regulate T-bet expression during an antitumor response mediated by anti-CTLA-4 remain to be e...

    journal_title:Cancer immunology research

    pub_type: 临床试验,杂志文章

    doi:10.1158/2326-6066.CIR-13-0155

    authors: Chen H,Fu T,Suh WK,Tsavachidou D,Wen S,Gao J,Ng Tang D,He Q,Sun J,Sharma P

    更新日期:2014-02-01 00:00:00

  • Pathogen-driven cancers and emerging immune therapeutic strategies.

    abstract::Infectious agents play an etiologic role in approximately 20% of cancer cases worldwide. Eleven pathogens (seven viruses, three parasites, and one bacterium) are known to contribute to oncogenesis either directly via the expression of their protein products or indirectly via chronic inflammation. Although prevention o...

    journal_title:Cancer immunology research

    pub_type: 杂志文章,评审

    doi:10.1158/2326-6066.CIR-13-0179

    authors: Vandeven N,Nghiem P

    更新日期:2014-01-01 00:00:00

  • Escalating regulation of 5T4-specific IFN-γ+ CD4+ T cells distinguishes colorectal cancer patients from healthy controls and provides a target for in vivo therapy.

    abstract::The relationship between the adaptive CD4+ T cell response and human cancer is unclear. The oncofetal antigen 5T4 is expressed on many human carcinomas, including colorectal cancer (CRC) cells, but has limited expression on normal tissues. We previously identified anti-5T4 CD4+ T cells in a proportion of CRC patients,...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-13-0035

    authors: Scurr M,Bloom A,Pembroke T,Srinivasan R,Brown C,Smart K,Bridgeman H,Davies M,Hargest R,Phillips S,Christian A,Hockey T,Gallimore A,Godkin A

    更新日期:2013-12-01 00:00:00

  • Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma.

    abstract::Increased angiogenesis and tumor-induced immune evasion are two mechanisms by which clear cell renal cell carcinoma (ccRCC) proliferate and metastasize; however, the relationship between these pathways in human ccRCC is poorly understood. We conducted a nested case-control study using 98 archived tumor samples from pa...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-13-0042

    authors: Joseph RW,Parasramka M,Eckel-Passow JE,Serie D,Wu K,Jiang L,Kalari K,Thompson RH,Huu Ho T,Castle EP,Cheville J,Kwon ED,Thompson EA,Parker A

    更新日期:2013-12-01 00:00:00

  • An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.

    abstract::A posteriori evidence suggests that radiotherapy to a targeted tumor can elicit an immune-mediated abscopal (ab-scopus, away from the target) effect in non-targeted tumors, when combined with an anti-cytotoxic T-lymphocyte antigen-4 monoclonal (CTLA-4) antibody. Concurrent radiotherapy and ipilimumab (a human monoclon...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-13-0115

    authors: Golden EB,Demaria S,Schiff PB,Chachoua A,Formenti SC

    更新日期:2013-12-01 00:00:00

  • Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial.

    abstract::Vaccination of patients with ovarian cancer with overlapping long peptides (OLP) from cancer-testis antigen NY-ESO-1 and poly-ICLC in Montanide-ISA-51 (Montanide) was found to consistently induce integrated immune responses (antibody, CD4(+), and CD8(+) T cells). Using detailed methods, we investigated the respective ...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-13-0089

    authors: Tsuji T,Sabbatini P,Jungbluth AA,Ritter E,Pan L,Ritter G,Ferran L,Spriggs D,Salazar AM,Gnjatic S

    更新日期:2013-11-01 00:00:00

  • GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.

    abstract::Ligation of GITR (glucocorticoid-induced tumor necrosis factor (TNF) receptor-related gene, or TNFRSF18) by agonist antibody has recently entered into early phase clinical trials for the treatment of advanced malignancies. Although the ability of GITR modulation to induce tumor regression is well-documented in preclin...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-13-0086

    authors: Schaer DA,Budhu S,Liu C,Bryson C,Malandro N,Cohen A,Zhong H,Yang X,Houghton AN,Merghoub T,Wolchok JD

    更新日期:2013-11-01 00:00:00

  • Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.

    abstract::High levels of human telomerase reverse transcriptase (hTERT) are detected in more than 85% of human cancers. Immunologic analysis supports that hTERT is a widely applicable target recognized by T cells and can be potentially studied as a broad cancer immunotherapeutic, or a unique line of defense against tumor recurr...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-13-0001

    authors: Yan J,Pankhong P,Shin TH,Obeng-Adjei N,Morrow MP,Walters JN,Khan AS,Sardesai NY,Weiner DB

    更新日期:2013-09-01 00:00:00

  • Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma.

    abstract::Ipilimumab and radiotherapy are commonly used to treat unresectable and metastatic melanoma. Results from preclinical studies and case reports suggest a biologic interaction between these two treatments. To understand the clinical implications of the interaction, we carried out a retrospective study reviewing records ...

    journal_title:Cancer immunology research

    pub_type: 杂志文章,评审

    doi:10.1158/2326-6066.CIR-13-0082

    authors: Barker CA,Postow MA,Khan SA,Beal K,Parhar PK,Yamada Y,Lee NY,Wolchok JD

    更新日期:2013-08-01 00:00:00

101 条记录 3/3 页 « 123 »